摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-phenyl-1,3-dihydro-imidazo[4,5-b]pyrazin-2-one | 438190-85-3

中文名称
——
中文别名
——
英文名称
5-phenyl-1,3-dihydro-imidazo[4,5-b]pyrazin-2-one
英文别名
5-phenyl-1,3-dihydroimidazo[4,5-b]pyrazin-2-one
5-phenyl-1,3-dihydro-imidazo[4,5-b]pyrazin-2-one化学式
CAS
438190-85-3
化学式
C11H8N4O
mdl
——
分子量
212.211
InChiKey
HMOJZFVMIKFVAQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    66.9
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    5-phenyl-1,3-dihydro-imidazo[4,5-b]pyrazin-2-one 以 ice-water 、 三氯氧磷 为溶剂, 生成 2-chloro-5-phenyl-1H-imidazo[4,5-b]pyrazine
    参考文献:
    名称:
    Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines
    摘要:
    提供了能够调节NPY5受体活性的替代螺环[异苯并呋喃-1,4′-哌啶]-3-酮和3H-螺环异苯并呋喃-1,4′-哌啶。这些化合物可用于在体内或体外调节NPY5受体的配体结合,并且在治疗各种疾病(例如,肥胖或暴食症等进食障碍、精神障碍、糖尿病和高血压等心血管疾病)方面对人类、驯养的伴侣动物和家畜动物特别有用。提供了用于治疗这些疾病的药物组合物和方法,以及用于检测NPY5受体的这些化合物的方法。
    公开号:
    US20030036652A1
点击查看最新优质反应信息

文献信息

  • Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
    申请人:Bakthavatchalam Rajagopal
    公开号:US20050033048A1
    公开(公告)日:2005-02-10
    Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and method for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.
    本文提供了能够调节NPY5受体活性的取代的spiro[异苯并呋喃-1,4'-哌啶]-3-酮和3H-spiro异苯并呋喃-1,4'-哌啶。这些化合物可以用于体内或体外调节NPY5受体的配体结合,并且在人类、宠物和家畜动物的多种疾病治疗中特别有用(例如,饮食失调如肥胖症或贪食症、精神障碍、糖尿病和心血管疾病如高血压)。提供了制药组合物和治疗这些疾病的方法,以及使用这些化合物检测NPY5受体的方法。
  • Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
    申请人:Pfizer Inc.
    公开号:US06566367B2
    公开(公告)日:2003-05-20
    Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.
    本发明提供了能够调节NPY5受体活性的取代的螺[异苯并呋喃-1,4'-哌啶]-3-酮和3H-螺异苯并呋喃-1,4'-哌啶类化合物。这些化合物可用于体内或体外调节配体与NPY5受体的结合,并在治疗多种疾病(例如,饮食失调,如肥胖症或贪食症,精神障碍,糖尿病和心血管疾病,如高血压)的人类、家养伴侣动物和家畜动物中特别有用。还提供了用于治疗这些疾病的制药组合物和方法,以及用于检测NPY5受体的方法。
  • Heteroaryl compounds, compositions thereof, and methods of treatment therewith
    申请人:Mortensen Deborah Sue
    公开号:US20090023724A1
    公开(公告)日:2009-01-22
    Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 , R 2 , L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    本文提供具有以下结构的杂环芳基化合物:其中R1,R2,L,X,Y,Z,Q,A和B的定义如下,包括有效量的杂环芳基化合物的组合物以及治疗或预防癌症,炎症状况,免疫状况,代谢状况以及通过抑制激酶通路可治疗或预防的状况的方法,包括向需要治疗的患者中给予有效量的杂环芳基化合物。
  • Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
    申请人:De Lombaert Stéphane
    公开号:US06943199B2
    公开(公告)日:2005-09-13
    Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.
    提供了能够调节NPY5受体活性的代替的spiro [异苯并呋喃-1,4'-哌啶] -3-酮和3H-spiroisobenzofuran-1,4'-哌啶。这些化合物可以用于体内或体外调节配体结合到NPY5受体,并在人类、家养伴侣动物和家畜动物的多种疾病治疗中特别有用(例如,饮食失调,如肥胖或贪食症,精神障碍、糖尿病和心血管疾病,如高血压)。提供了用于治疗这些疾病的药物组合物和方法,以及用于检测NPY5受体的这些化合物的方法。
  • METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS
    申请人:Mortensen Deborah Sue
    公开号:US20110245245A1
    公开(公告)日:2011-10-06
    Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 , R 2 , L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    本文提供了具有以下结构的杂环芳基化合物:其中R1、R2、L、X、Y、Z、Q、A和B的定义如下,包括有效量的杂环芳基化合物的组合物,并且治疗或预防癌症、炎症状况、免疫病状况、代谢病状况和通过抑制激酶途径可治疗或预防的病状况的方法包括向需要治疗的患者中施用有效量的杂环芳基化合物。
查看更多

同类化合物

腔肠素HCP 腔肠素F 腔肠素-H 腔肠素 恩扎托韦 咪唑并[1.2-b]吡嗪-3-甲酸乙酯 咪唑并[1,2-a]吡嗪-8-胺 咪唑并[1,2-a]吡嗪-6-硫醇 咪唑并[1,2-a]吡嗪-6-甲腈 咪唑并[1,2-a]吡嗪-5(1H)-酮 咪唑并[1,2-a]吡嗪-3-甲醛 咪唑并[1,2-a]吡嗪-3-基甲醇 咪唑并[1,2-a]吡嗪-2-羧酰胺 咪唑并[1,2-a]吡嗪-2-甲醛 咪唑并[1,2-a]吡嗪-2-甲酸 咪唑并[1,2-a]吡嗪-2-甲腈 咪唑并[1,2-A]吡嗪-2-胺 咪唑并[1,2-A]吡嗪-2-羧酸甲酯 咪唑并[1,2-A]吡嗪-2-甲酸乙酯 咪唑并[1,2-A]吡嗪-2-甲胺 吲哚[1,2-A]吡嗪 乙基2-甲基咪唑并[1,2-a]吡嗪-3-羧酸酯 Tirasemtiv(CK-2017357)抑制剂 8-茶碱汞乙酸酯 8-甲氧基咪唑并[1,2-a]吡嗪 8-甲基-2-(三氟甲基)咪唑并[1,2-a]吡嗪 8-溴咪唑并[1,2-a]吡嗪 8-溴-6-甲基咪唑并[1,2-A]吡嗪 8-溴-6-氯咪唑并[1,2-a]吡嗪 8-溴-6-氯-3-甲基咪唑并[1,2-A]吡嗪 8-溴-3-碘咪唑并[1,2-a]吡嗪 8-溴-2-三氟甲基咪唑并[1,2-a]吡嗪 8-氯咪唑并[1,2-a]吡嗪-2-羧酸甲酯 8-氯咪唑并[1,2-a]吡嗪 8-氯-3-碘咪唑并[1,2-a]吡嗪 8-氯-3-甲基咪唑并[1,2-A]吡嗪 8-氯-2-甲基咪唑并[1,2-a]吡嗪 8-氯-2-乙基-咪唑并[1,2-a]吡嗪 8-氯-2-三氟甲基咪唑并[1,2-a]吡嗪 6-甲基咪唑并[1,2-a]吡嗪-2-羧酸 6-甲基-N-苯基咪唑并[1,2-a]吡嗪-3-胺 6-甲基-8-(甲基硫代)-咪唑并[1,2-a]吡嗪 6-溴咪唑并[1,2-a]吡嗪-8-胺 6-溴咪唑并[1,2-a]吡嗪-3-胺 6-溴咪唑并[1,2-a]吡嗪-3-甲醛 6-溴吡嗪2-羧酸 6-溴-N-甲基咪唑并[1,2-a]吡嗪-8-胺 6-溴-N-乙基咪唑并[1,2-a]吡嗪-8-胺 6-溴-8-苯基咪唑并[1,2-a]吡嗪 6-溴-8-甲硫基咪唑并[1,2-A]吡嗪